The Outcome of Treatment for Patients with Borrmann Type 4 Advanced Gastric Cancer - Journal of Cancer Therapy

JCT > Vol.7 No.12, November 2016

The Outcome of Treatment for Patients with Borrmann Type 4 Advanced Gastric Cancer ()

HTML XML

Download as PDF (Size: 1785KB) PP. 953-962

DOI: 10.4236/jct.2016.712092 1,634 Downloads 3,652 Views Citations

Author(s)

Rie Tamaki^1,2*, Fumio Amano², Tohru Hashida¹, Hironaga Satake³, Hisateru Yasui³, Akihito Tsuji^3,4

Affiliation(s)

¹Clinical Trial Management Center, Kobe City Medical Center General Hospital, Kobe, Japan.
²Laboratory of Biodefense & Regulation, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan.
³Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
⁴Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.

ABSTRACT

Introduction: The survival rate of patients with Borrmann type 4 advanced gastric cancer is extremely poor in comparison to patients with gastric cancers of other histological types. An optimal chemotherapeutic regimen has yet to be determined. Patients and Methods: We retrospectively examined the outcome of patients who were treated for Borrmann type 4 advanced gastric cancer from July 2011 and June 2015. Results: The data from 42 cases were collected for this study. Of the 42 cases, 13 cases (31.0%) were locally advanced and 29 cases (69.0%) were metastatic advanced. Median Overall Survival (OS) for locally advanced cancer was 29.6 months and for metastatic advanced cancer was 11.5 months. The presence or absence of peritoneal metastases did not affect survival (8.9 and 11.5 months, respectively; p = 0.831). In the 23 patients who received chemotherapy, S-1 plus cisplatin was prescribed as first-line treatment in 16 cases (69.5%). Other treatment regimens included capecitabine plus cisplatin and S-1 plus oxaliplatinin one each (4.3%), S-1 monotherapy in two (8.6%), and capecitabine monotherapy, paclitaxel, and docetaxel in one each (4.3%). We found no median OS difference between S-1 plus cisplatin and other treatments (20.7 and 19.3 months; p = 0.094). Conclusion: We found that S-1 plus cisplatin treatment does not improve OS in patients with Borrmann type 4 advanced gastric cancer compared with other chemotherapeutic regimens.

KEYWORDS

Gastric Cancer, Adenocarcinoma, Scirrhous, Cisplatin, Chemotherapy, Metastasis

Share and Cite:

Tamaki, R. , Amano, F. , Hashida, T. , Satake, H. , Yasui, H. and Tsuji, A. (2016) The Outcome of Treatment for Patients with Borrmann Type 4 Advanced Gastric Cancer. Journal of Cancer Therapy, 7, 953-962. doi: 10.4236/jct.2016.712092.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies